Loading
PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.00, clinical 0.99).
In plain words · PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at PSMD2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMD2 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMD2: RNA tissue enhanced (skeletal muscle 300 nTPM); high antibody staining in 24 normal tissues; highest cancer staining melanoma (9 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMD2 tissue; Open Targets ENSG00000175166 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Boldin M.P. et al, FEBS Lett, 1995, "A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its 'death domain'". Source.
Sources: HGNC HGNC:9559 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13200 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000175166 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Binds to the intracellular domain of tumour necrosis factor type 1 receptor. The binding domain of TRAP1 and TRAP2 resides outside the death domain of TNFR1. Locus 3q27.1 (HGNC).
RNA: tissue enhanced (skeletal muscle 300 nTPM), detected in all normal tissues.
Medium: Adrenal gland, Cerebral cortex, Cervix, Fallopian tube, Liver, Oral mucosa, Pancreas, Placenta.
Medium only: cervical cancer, head and neck cancer, skin cancer.
HPA PSMD2 tissue · HPA PSMD2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMD2" OR ABSTRACT:"PSMD2" OR TITLE:"proteasome 26S subunit ubiquitin receptor, non-ATPase 2" OR ABSTRACT:"proteasome 26S subunit ubiquitin receptor, non-ATPase 2" OR TITLE:"26S proteasome non-ATPase regulatory subunit 2" OR ABSTRACT:"26S proteasome non-ATPase regulatory subunit 2" OR TITLE:"S2" OR ABSTRACT:"S2" OR TITLE:"P97" OR ABSTRACT:"P97" OR TITLE:"TRAP2" OR ABSTRACT:"TRAP2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMD2, not a curated reading list.